NCT05560009View on ClinicalTrials.gov

An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas

CompletedOBSERVATIONAL
Enrollment

9

Participants

Timeline

Start Date

November 10, 2022

Primary Completion Date

July 9, 2024

Study Completion Date

July 9, 2024

Conditions
Recurrent Soft Tissue SarcomaResectable Soft Tissue SarcomaSoft Tissue Sarcoma
Interventions
DRUG

Fluorodopa F 18

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo PET/MRI

PROCEDURE

Positron Emission Tomography

Undergo PET/MRI

RADIATION

Radiation Therapy

Receive standard of care radiation therapy

PROCEDURE

Surgical Procedure

Undergo standard of care surgery

Trial Locations (1)

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05560009 - An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas | Biotech Hunter | Biotech Hunter